Breaking News, Collaborations & Alliances

ViralClear, AMRI Enter COVID-19 Partnership

For the manufacture of merimepodib API in development for the potential treatment of COVID-19.

By: Contract Pharma

Contract Pharma Staff

ViralClear Pharmaceuticals, supported by Albany Molecular Research Inc., (AMRI), a global contract research, development, and manufacturing organization (CDMO), is undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.   “As part of our ongoing development and commercialization strategy we are delighted to be working with AMRI as our...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters